173 related articles for article (PubMed ID: 32661774)
1. Chitosan Hydrogels for Synergistic Delivery of Chemotherapeutics to Triple Negative Breast Cancer Cells and Spheroids.
Schneible JD; Young AT; Daniele MA; Menegatti S
Pharm Res; 2020 Jul; 37(7):142. PubMed ID: 32661774
[TBL] [Abstract][Full Text] [Related]
2. A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer.
Vogus DR; Evans MA; Pusuluri A; Barajas A; Zhang M; Krishnan V; Nowak M; Menegatti S; Helgeson ME; Squires TM; Mitragotri S
J Control Release; 2017 Dec; 267():191-202. PubMed ID: 28823957
[TBL] [Abstract][Full Text] [Related]
3. Tailoring the Chemical Modification of Chitosan Hydrogels to Fine-Tune the Release of a Synergistic Combination of Chemotherapeutics.
Schneible JD; Singhal A; Lilova RL; Hall CK; Grafmüller A; Menegatti S
Biomacromolecules; 2019 Aug; 20(8):3126-3141. PubMed ID: 31310515
[TBL] [Abstract][Full Text] [Related]
4. Drug-loaded implantable surgical cavity-adaptive hydrogels for prevention of local tumor recurrence.
Zhuang B; Chen T; Xiao Z; Jin Y
Int J Pharm; 2020 Mar; 577():119048. PubMed ID: 31978462
[TBL] [Abstract][Full Text] [Related]
5. Modified gaphene oxide (GO) particles in peptide hydrogels: a hybrid system enabling scheduled delivery of synergistic combinations of chemotherapeutics.
Schneible JD; Shi K; Young AT; Ramesh S; He N; Dowdey CE; Dubnansky JM; Lilova RL; Gao W; Santiso E; Daniele M; Menegatti S
J Mater Chem B; 2020 May; 8(17):3852-3868. PubMed ID: 32219269
[TBL] [Abstract][Full Text] [Related]
6. Combination of using prodrug-modified cationic liposome nanocomplexes and a potentiating strategy via targeted co-delivery of gemcitabine and docetaxel for CD44-overexpressed triple negative breast cancer therapy.
Fan Y; Wang Q; Lin G; Shi Y; Gu Z; Ding T
Acta Biomater; 2017 Oct; 62():257-272. PubMed ID: 28859899
[TBL] [Abstract][Full Text] [Related]
7. Co-delivery of doxorubicin, docosahexaenoic acid, and α-tocopherol succinate by nanostructured lipid carriers has a synergistic effect to enhance antitumor activity and reduce toxicity.
Lages EB; Fernandes RS; Silva JO; de Souza ÂM; Cassali GD; de Barros ALB; Miranda Ferreira LA
Biomed Pharmacother; 2020 Dec; 132():110876. PubMed ID: 33113428
[TBL] [Abstract][Full Text] [Related]
8. A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis.
Pattarawat P; Hunt JT; Poloway J; Archibald CJ; Wang HR
Cancer Chemother Pharmacol; 2021 Sep; 88(3):415-425. PubMed ID: 34043046
[TBL] [Abstract][Full Text] [Related]
9. Formulation of a triple combination gemcitabine plus romidepsin + cisplatin regimen to efficaciously and safely control triple-negative breast cancer tumor development.
Pattarawat P; Wallace S; Pfisterer B; Odoi A; Wang HR
Cancer Chemother Pharmacol; 2020 Jan; 85(1):141-152. PubMed ID: 31865420
[TBL] [Abstract][Full Text] [Related]
10. Chitosan-dipeptide hydrogels as potential anticancer drug delivery systems.
Shim J; Kang J; Yun SI
Int J Biol Macromol; 2021 Sep; 187():399-408. PubMed ID: 34314799
[TBL] [Abstract][Full Text] [Related]
11. Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(d,l-lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival.
Allison Logan S; Brissenden AJ; Szewczuk MR; Neufeld RJ
Drug Des Devel Ther; 2017; 11():2239-2250. PubMed ID: 28814832
[TBL] [Abstract][Full Text] [Related]
12. Co-delivery of paclitaxel and gemcitabine by methoxy poly(ethylene glycol)-poly(lactide-coglycolide)-polypeptide nanoparticles for effective breast cancer therapy.
Dong S; Guo Y; Duan Y; Li Z; Wang C; Niu L; Wang N; Ma M; Shi Y; Zhang M
Anticancer Drugs; 2018 Aug; 29(7):637-645. PubMed ID: 29846247
[TBL] [Abstract][Full Text] [Related]
13. Heterotelechelic polymer prodrug nanoparticles: Adaptability to different drug combinations and influence of the dual functionalization on the cytotoxicity.
Vinciguerra D; Jacobs M; Denis S; Mougin J; Guillaneuf Y; Lazzari G; Zhu C; Mura S; Couvreur P; Nicolas J
J Control Release; 2019 Feb; 295():223-236. PubMed ID: 30611900
[TBL] [Abstract][Full Text] [Related]
14. Lymph cancer chemotherapy: delivery of doxorubicin-gemcitabine prodrug and vincristine by nanostructured lipid carriers.
Ni S; Qiu L; Zhang G; Zhou H; Han Y
Int J Nanomedicine; 2017; 12():1565-1576. PubMed ID: 28280326
[TBL] [Abstract][Full Text] [Related]
15. Development of Liposomal Gemcitabine with High Drug Loading Capacity.
Tamam H; Park J; Gadalla HH; Masters AR; Abdel-Aleem JA; Abdelrahman SI; Abdelrahman AA; Lyle LT; Yeo Y
Mol Pharm; 2019 Jul; 16(7):2858-2871. PubMed ID: 31136710
[TBL] [Abstract][Full Text] [Related]
16. Combination of Doxorubicin with Gemcitabine-Incorporated G-Quadruplex Aptamer Showed Synergistic and Selective Anticancer Effect in Breast Cancer Cells.
Joshi M; Choi JS; Park JW; Doh KO
J Microbiol Biotechnol; 2019 Nov; 29(11):1799-1805. PubMed ID: 31546295
[TBL] [Abstract][Full Text] [Related]
17. Loading of Gemcitabine on chitosan magnetic nanoparticles increases the anti-cancer efficacy of the drug.
Parsian M; Unsoy G; Mutlu P; Yalcin S; Tezcaner A; Gunduz U
Eur J Pharmacol; 2016 Aug; 784():121-8. PubMed ID: 27181067
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation loaded with paclitaxel for the treatment of pancreatic cancer using ultrasound-targeted microbubble destruction.
Logan KA; Nesbitt H; Callan B; Gao J; McKaig T; Taylor M; Love M; McHale AP; Callan JF
Eur J Pharm Biopharm; 2021 Aug; 165():374-382. PubMed ID: 34038797
[TBL] [Abstract][Full Text] [Related]
19. Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines.
Zoli W; Ricotti L; Barzanti F; Dal Susino M; Frassineti GL; Milandri C; Casadei Giunchi D; Amadori D
Int J Cancer; 1999 Jan; 80(3):413-6. PubMed ID: 9935183
[TBL] [Abstract][Full Text] [Related]
20. Codelivery of anti-cancer agents via double-walled polymeric microparticles/injectable hydrogel: A promising approach for treatment of triple negative breast cancer.
Davoodi P; Ng WC; Srinivasan MP; Wang CH
Biotechnol Bioeng; 2017 Dec; 114(12):2931-2946. PubMed ID: 28832946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
